Last reviewed · How we verify
RAL plus ABC/3TC
This combination uses raltegravir (an integrase inhibitor) plus abacavir and lamivudine (nucleoside reverse transcriptase inhibitors) to suppress HIV replication through multiple mechanisms.
This combination uses raltegravir (an integrase inhibitor) plus abacavir and lamivudine (nucleoside reverse transcriptase inhibitors) to suppress HIV replication through multiple mechanisms. Used for HIV-1 infection.
At a glance
| Generic name | RAL plus ABC/3TC |
|---|---|
| Also known as | INSTI-Based Regimen |
| Sponsor | Juan A. Arnaiz |
| Drug class | Antiretroviral combination therapy (integrase inhibitor + nucleoside reverse transcriptase inhibitors) |
| Target | HIV integrase, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Raltegravir blocks HIV integrase, preventing viral DNA from integrating into the host genome. Abacavir and lamivudine are nucleoside reverse transcriptase inhibitors that block reverse transcription of viral RNA into DNA. Together, this triple-drug regimen targets different steps of the HIV replication cycle to achieve potent viral suppression.
Approved indications
- HIV-1 infection
Common side effects
- Diarrhea
- Nausea
- Headache
- Hypersensitivity reaction (abacavir)
- Lipodystrophy
- Lactic acidosis
Key clinical trials
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine (PHASE3)
- Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (PHASE3)
- Study of Options for Second-Line Effective Combination Therapy (SELECT) (PHASE3)
- Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I (PHASE3)
- Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients
- Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RAL plus ABC/3TC CI brief — competitive landscape report
- RAL plus ABC/3TC updates RSS · CI watch RSS
- Juan A. Arnaiz portfolio CI